Literature DB >> 3691595

Factors responsible for interindividual differences in the dose requirement of phenprocoumon.

D Trenk1, H Althen, E Jähnchen, T Meinertz, S Oie.   

Abstract

The total and unbound plasma concentrations of phenprocoumon and the prothrombin complex activity were determined in 51 patients on phenprocoumon. A 7-fold difference in the dosing rate (10-70 micrograms/kg/day) was required to maintain the prothrombin complex activity at 11-30% of normal. The variation in dosing requirement was mainly due to interindividual differences in the intrinsic clearance of phenprocoumon and only to a minor degree to differences in sensitivity to it. On average patients with myocardial infarction required only 2/3 of the daily dose of phenprocoumon of post cardiac surgery patients and patients with thrombosis and emboli. That difference appeared to be due to higher clearance in surgical patients and to greater resistance to phenprocoumon in patients with thrombosis and emboli. The total clearance in patients varied approximately 5-fold. It was better predicted by the interindividual intrinsic clearance (r = 0.84) than by the unbound fraction (r = 0.15).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691595     DOI: 10.1007/bf00610379

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Individual variation in the response to phenprocoumon.

Authors:  S Husted; F Andreasen
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

3.  [Pharmacokinetic aspects of overdosage and intoxication with oral anticoagulant drugs (author's transl)].

Authors:  E Jähnchen; T Meinertz
Journal:  Arzneimittelforschung       Date:  1977

Review 4.  Some aspects of the pharmacology of oral anticoagulants.

Authors:  W W Coon; P W Willis
Journal:  Clin Pharmacol Ther       Date:  1970 May-Jun       Impact factor: 6.875

Review 5.  The pharmacological basis of oral anticoagulant therapy.

Authors:  P M Aggeler; R A O'Reilly
Journal:  Thromb Diath Haemorrh Suppl       Date:  1966

Review 6.  Aging and drug disposition: an update.

Authors:  D L Schmucker
Journal:  Pharmacol Rev       Date:  1985-06       Impact factor: 25.468

7.  Pharmacokinetics and pharmacodynamics of warfarin at steady state.

Authors:  P A Routledge; P H Chapman; D M Davies; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

8.  Pharmacokinetics of phenprocoumon in man investigated using a gas chromatographic method of drug analysis.

Authors:  N Heni; P Glogner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-05       Impact factor: 3.000

9.  Properties of 3-(1-phenyl-propyl)-4-oxycoumarin (marcoumar) in the plasma when tested in normal cases and under the influence of drugs.

Authors:  K Seiler; F Duckert
Journal:  Thromb Diath Haemorrh       Date:  1968-07-31

10.  Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.

Authors:  A Yacobi; J A Udall; G Levy
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

View more
  4 in total

Review 1.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not.

Authors:  Cordula Meyer zu Schwabedissen; Vera Mevissen; Fabian Schmitz; Seth Woodruff; Georg Langebartels; Thomas Rau; Klaus Zerres; Rainer Hoffmann; Jan R Ortlepp
Journal:  Eur J Clin Pharmacol       Date:  2006-07-18       Impact factor: 2.953

Review 3.  Clinically important drug interactions with anticoagulants. An update.

Authors:  S Harder; P Thürmann
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

4.  Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.

Authors:  Khaled Abduljalil; Simone Lazar; Michael Natanzon; Weidong Wu; Gregor Zadoyan; Benedict Steffens; Victoria Kohl; Klaus Mörike; Dorota Tomalik-Scharte; Julia Stingl; Matthias Schwab; Job Harenberg; Christoph Gleiter; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.